Skip to search formSkip to main contentSkip to account menu

pegaptanib

Known as: pegaptanib [Chemical/Ingredient] 
A 28-mer RNA aptamer covalently linked to two branched 20-kD polyethylene glycol (PEG) chains, with anti-angiogenic activity. Pegaptanib binds and… 
National Institutes of Health

Related topics

Related topics

6 relations
0.09 ML pegaptanib 3.33 MG/ML Prefilled Syringe [Macugen]Pegaptanib Sodium

Broader (1)

Aptamers, Nucleotide

Narrower (3)

EYE 001MacugenNX1838

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Therapeutic aptamers: developmental potential as anticancer drugs
Aptamers, composed of single-stranded DNA or RNA oligonucleotides that interact with target molecules through a specific three… 
Review
2014
Review
2014
Safety monitoring of ophthalmic biologics: a systematic review of pre- and postmarketing safety data.
Abstract Purpose: The present study evaluates the safety of the biologics approved for the treatment of ocular diseases. Methods… 
2014
2014
Next-generation AMD drugs to wed blockbusters
2012
2012
Ranibizumab for eyes previously treated with pegaptanib or bevacizumab without clinical response.
BACKGROUND AND OBJECTIVE To assess the safety and efficacy of ranibizumab in patients who had inadequate response to pegaptanib… 
Highly Cited
2011
Highly Cited
2011
The safety of using anti-VEGF: Is there strength in numbers? Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with…
The safety of using anti-VEGF remains a hot topic. There are not many retinal specialists who have not “fought” at one stage or… 
Highly Cited
2010
Highly Cited
2010
Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab.
2008
2008
Die Therapie der vaskularisierten serösen Pigmentepithelabhebung bei AMD – Beobachtungen nach Wechsel des intravitrealen Medikamentes bei Therapieversagen
Einleitung: Methode: Ergebnisse: Schlussfolgerungen: Introduction: Method: Results: Conclusion: 
2008
2008
Évolution des pratiques pour la réalisation des injections intravitréennes
2007
2007
STANDARDIZED VISUAL ACUITY RESULTS ASSOCIATED WITH PRIMARY VERSUS SECONDARY BEVACIZUMAB (AVASTIN) TREATMENT FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION
Purpose: To compare standardized visual outcomes and macular thickness changes associated with primary and secondary bevacizumab… 
2007
2007
Anti-VEGF for neovascular ARMD: visual improvement as the goal of therapy?
There has been dramatic progress in anti-VEGF therapy, but future guidelines are needed 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)